IHS Chemical Week

EnviroTech :: Regulatory :: Regulatory: Pesticides

Monsanto signs option agreement to support biologicals platform

8:01 AM MST | January 13, 2014 | Rebecca Coons

Tekmira Pharmaceuticals, a leading developer of RNA interference (RNAi) therapeutics, announced today that it has signed an option agreement under which Monsanto may obtain a license to use Tekmira's proprietary delivery technology. The transaction will support the application of Tekmira's proprietary delivery technology and related intellectual property (IP) for use in agriculture, Tekmira says. The company says the potential value of the transaction could reach up to $86.2 million following the successful completion of milestones. Tekmira expects to receive a...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa